A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer.
CLEVAR
A clinical enabling study of bone-marrow vascular leak measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in healthy subjects and patients with Acute Myeloid Leukaemia (AML).
DISCUS
A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.
ECLIPSE
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.
UROPANC
Early detection of pancreatic ductal adenocarcinoma (PDAC) using a panel of biomarkers.
In set up
STARPAC2
Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer.
In follow-up (closed to recruitment)
BARBICAN
A randomised, open-label phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer.
CALYPSO
MEDI4736 combinations in metastatic renal cell carcinoma.
PAKT
A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination with Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer.
PINBALL
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
Closed
ABACUS
A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder.
ARB
Phase II window of opportunity study of short-term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.
GAMMA
A novel, single arm phase II study for relapsed germ cell tumours with poor prognosis.
HIVEC-II
A phase II, open label, multicentre, randomised controlled trial comparing hyperthermia plus mitomycin to mitomycin alone, in patients with intermediate risk non-muscle invasive bladder cancer.
IMPACT
IMaging pilot study of the αvβ6 integrin radiotracer [18F]-A20FMDV2 in PAtients with solid Cancer Types.
MANTA
A randomized Phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen receptor-positive advanced or metastatic breast cancer.
PEBBLE
A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder.
RAFT
Robotic Surgery After Focal Ablation Therapy.
STARPAC
A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-Paclitaxel for pancreatic cancer.
TORCMEK
A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
TRICREST
A phase II, single arm, multicentre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer.
